Marijuana Relieves Chronic Pain, Research Shows


Three Puffs a Day Helped People With Nerve Pain, Study Finds
cannabis sativa leaves

Aug. 30, 2010 — Three puffs a day of cannabis, better known as marijuana, helps people with chronic nerve pain due to injury or surgery feel less pain and sleep better, a Canadian team has found.

”It’s been known anecdotally,” says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal. “About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,” he tells WebMD.

But Ware’s study is more scientific — a clinical trial in which his team compared placebo with three different doses of cannabis. The research is published in CMAJ, the Canadian Medical Association Journal.

The new study ”adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,” Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.

Marijuana for Pain Relief: Study Details

Ware evaluated 21 men and women, average age 45, who had chronic nerve pain (also called neuropathic pain). A typical example, Ware tells WebMD, is a patient who had knee surgery and during the course of the operation the surgeon may have had no choice but to cut a nerve, leading to chronic pain after the surgery.

Ware’s team tried three different potencies of marijuana, with the highest a concentration at 9.4% tetrahydrocannabinol (THC) herbal cannabis. He also tested 2.5% and 6% THC.

”Each person was in the study for two months, and used all four strengths [including placebo],” Ware says. He rotated them through the four strengths in different orders, and they didn’t know which they were using.

The cannabis was put into gelatin capsules, then put into the bowl of a pipe. Each person was told to inhale for five seconds while the cannabis was lit, hold the smoke in their lungs for 10 seconds, and then exhale.

They did this single puff three times a day for five days for each of the doses and the placebo. The participants were allowed to continue on their routine pain medications.

After each of the five-day trials, participants rated their pain on a scale of zero to 10, with 10 being the worst.

The highest dose, 9.4%, provided relief, Ware says. “They reduced their pain down to 5.4,” Ware says. “Those on placebo were at 6.1.”

Although that difference may seem modest, ”any reduction in pain is important,” Ware says.

The concentration of 9.4%, Ware says, is lower than that found in marijuana on the street. “On the street, it’s 10% to 15% THC, more or less,” he says.

“We’ve shown again that cannabis is analgesic,” Ware says. “Clearly, it has medical value.”

Side effects were reported, including headache, dry eyes, numbness, cough, and a burning sensation in the area with pain.

The cannabis relieves pain, Ware says, by ”changing the way the nerves function.”

Marijuana for Pain Relief: Second Opinion

Marijuana’s pain-relieving potential is worth investigating, McQuay says in his commentary.

He points out the average daily pain relief was lower, ”but not hugely so,” for people taking the highest concentration of marijuana.

The cannabis, he tells WebMD in an email interview, “may help some patients who have limited relief from other remedies, but current cannabis formulations are unlikely to replace existing treatments.”

Among McQuay’s disclosures are serving as an advisory board member for Pfizer’s Data Safety and Monitoring Board, as a consultant for Sanofi and other companies, and receiving royalties for a textbook on pain.

bleeding in hemophilia


In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti-FVIII antibodies, known as `inhibitors`. Drugs insensitive to such antibodies, either recombinant or plasma-derived, are called factor VIII “by-passing“ agents and used for treatment of bleeding in people with inhibitors.
OBJECTIVES: To determine the clinical effectiveness of recombinant FVIIa concentrate in comparison to plasma-derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
SEARCH STRATEGY: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Coagulopathies Trials Register which comprises references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Date of the most recent search of the Group`s Trials Register: 07 July 2010.
SELECTION CRITERIA: Randomised (RCTs) and quasi-randomised controlled clinical trials comparing recombinant FVIIa concentrate (rFVIIa) to human plasma-derived concentrates (high-dose human or recombinant FVIII or FIX concentrate; prothrombin complex concentrates (PCCs); activated prothrombin complex concentrate (aPCC)) in persons with haemophilia. Comparisons with animal derived products were excluded.
DATA COLLECTION AND ANALYSIS: Two authors independently assessed trials (eligibility and risk of bias) and extracted data. No meta-analysis was performed due to unavailability of outcomes and comparisons common to the included studies.
MAIN RESULTS: A total of ten trials were identified, two of which (total of 69 participants) were eligible for analysis. Both trials showed methodological flaws and did not show superiority of one treatment over the other. Both the treatments showed that (rFVIIa and aPCC appeared to have a similar haemostatic effect in both studies, without increasing thromboembolic risk.
AUTHORS’ CONCLUSIONS: Although the main conclusion should be the need for further randomised controlled trials, we conclude that both rFVIIa and aPCC can be used to treat bleeding in haemophiliacs with inhibitors.

Metformin: Taking Away the Candy for Cancer?


Metformin is widely used in the treatment of diabetes mellitus type 2 where it reduces insulin resistance and diabetes-related morbidity and mortality. Population-based studies show that metformin treatment is associated with a dose-dependent reduction in cancer risk. The metformin treatment also increases complete pathological tumour response rates following neoadjuvant chemotherapy for breast cancer, suggesting a potential role as an anti-cancer drug. Diabetes mellitus type 2 is associated with insulin resistance, elevated insulin levels and an increased risk of cancer and cancer-related mortality. This increased risk may be explained by activation of the insulin- and insulin-like growth factor (IGF) signaling pathways and increased signalling through the oestrogen receptor. Reversal of these processes through reduction of insulin resistance by the oral anti-diabetic drug metformin is an attractive anti-cancer strategy. Metformin is an activator of AMP-activated protein kinase (AMPK) which inhibits protein synthesis and gluconeogenesis during cellular stress. The main downstream effect of AMPK activation is the inhibition of mammalian target of rapamycin (mTOR), a downstream effector of growth factor signalling. mTOR is frequently activated in malignant cells and is associated with resistance to anticancer drugs. Furthermore, metformin can induce cell cycle arrest and apoptosis and can reduce growth factor signalling. This review discusses the role of diabetes mellitus type 2 and insulin resistance in carcinogenesis, the preclinical rationale and potential mechanisms of metformin’s anti-cancer effect and the current and future clinical developments of metformin as a novel anti-cancer drug.